<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30652747</article-id><article-id pub-id-type="pmc">6326447</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0106</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Importance of Intra-aortic Pulse Pressure After Anterior
ST-segment Elevation Myocardial Infarction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gul</surname><given-names>Ilker</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Cerit</surname><given-names>Levent</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Senturk</surname><given-names>Bihter</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Alkan</surname><given-names>Mustafa Beyaz&#x00131;t</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Kemal</surname><given-names>Hatice</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Cerit</surname><given-names>Zeynep</given-names></name><xref ref-type="aff" rid="aff4">4</xref><role>MD, MS</role></contrib><contrib contrib-type="author"><name><surname>Yaman</surname><given-names>Belma</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Usalp</surname><given-names>Songul</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Duygu</surname><given-names>Hamza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiology, Near East University Faculty of Medicine,
Nicosia, Cyprus. </aff><aff id="aff2">
<label>2</label> Department of Cardiology, Dokuz Eyl&#x000fc;l University Faculty of
Medicine, Izmir, Turkey. </aff><aff id="aff3">
<label>3</label> Department of Cardiology, Kas State Hospital, Antalya, Turkey. </aff><aff id="aff4">
<label>4</label> Department of Pediatric Cardiology, Near East University Faculty of
Medicine, Nicosia, Cyprus. </aff><author-notes><corresp id="c1">Correspondence Address: Levent Cerit, Near East University
Hospital, Near East Boulevard, Nicosia, Cyprus, Zip Code: 99138. E-mail:
<email>drcerit@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2018</year></pub-date><volume>33</volume><issue>6</issue><fpage>579</fpage><lpage>587</lpage><history><date date-type="received"><day>11</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>09</day><month>7</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To evaluate the association of pulse pressure (PP) with mortality and major
adverse cardiac events (MACE) in one-year period after anterior ST-elevation
myocardial infarction (A-STEMI).</p></sec><sec><title>Methods</title><p>A total of 261 consecutive patients whose blood pressure was measured with
the aid of a catheter before primary percutaneous coronary intervention
(PPCI) between August 2016 and February 2017 were included in the study. The
patients were divided into three groups according to pulse pressure (PP)
(Group 1, PP&#x0003c;35 mmHg; Group 2, 35&#x02264;PP&#x02264;50 mmHg; Group 3,
PP&#x0003e;50 mmHg).</p></sec><sec><title>Results</title><p>The mean age of the patients was 63.4&#x000b1;14.1 years, and 206 of them were
male. The groups were similar in terms of age and diastolic blood pressure
(DBP). The ratio of female patients in Group 1 was higher, and their
systolic blood pressure (SBP) was lower than those from the other groups
(<italic>P</italic>=0.005 <italic>vs</italic>.
<italic>P</italic>=0.042). The rates of MACE and mortality were higher in
Group 1. The predictive PP values were calculated to be 42.5 mmHg for
development of MACE and 41.5 mmHg for mortality. One-year survival ratio was
worse in Group 1 than in the others according to Kaplan-Meier analysis
(<italic>P</italic>&#x0003c;0.001).</p></sec><sec><title>Conclusion</title><p>The values of PP which was measured intra-aortically in patients with A-STEMI
were associated with mortality and MACE in the one-year follow-up
period.</p></sec></abstract><kwd-group><kwd>Myocardial Infarction</kwd><kwd>Treatment Outcome</kwd><kwd>Cardiac Catheterization</kwd><kwd>ST Elevation Myocardial Infarction</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="40%" span="1"/><col width="05%" span="1"/><col width="10%" span="1"/><col width="35%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#eaeaea" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#eaeaea" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ACS</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Acute coronary
syndromes</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>LVEDP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Left ventricular
end-diastolic pressure</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AMI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Acute myocardial
infarction</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>LVEF</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Left ventricular
ejection fraction</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ANOVA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Analysis of
variance</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>MACE</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Major adverse
cardiac events</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AUC</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Area under the
curve</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>MRI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Magnetic resonance
imaging</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>A-STEMI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Anterior
ST-elevation myocardial infarction</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>PAD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Diastolic arterial
pressure</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>c-TnI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Cardiac
troponin-I</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>PAS</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Systolic arterial
pressure</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Confidence
interval</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>PP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Pulse
pressure</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CK-MB</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Creatinine
kinase-myocardial band</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>PPCI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Primary
percutaneous coronary intervention</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CO</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Cardiac
output</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>RAAS</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>=
Renin-angiotensin-aldosterone system</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CT</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Computed
tomography</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>Re-MI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Re-myocardial
infarction</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>DBP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Diastolic blood
pressure</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ROC</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Receiver operating
characteristic</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>DtB</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>=
Door-to-balloon</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>SBP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Systolic blood
pressure</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ECG</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>=
Electrocardiogram</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>SD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Standard
deviation</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>GFR</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Glomerular
filtration rate</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>StD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>=
Symptom-to-door</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>Gp</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>=
Glycoprotein</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>STEMI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= ST-elevation
myocardial infarction</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>HR</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Hazard
ratio</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>STXs</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= SYNTAX
score</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>IABP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Intra-aortic
balloon pump</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>TIMI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Thrombolysis in
myocardial infarction</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>IV</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>=
Intravenous</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Acute myocardial infarction (AMI) is one of the leading causes of mortality
worldwide<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. The most important cause of this condition is the
decline of cardiac functions after AMI. This decline's severity is associated with
the localization and size of the infarct region<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. The inadequacy of
cardiac functions causes acute changes in hemodynamic parameters, and eventually,
cardiac output (CO) decreases. The neuroendocrine system is activated in response to
an impaired CO. The secretory rhythm of vasopressor substances such as noradrenaline
and angiotensinogen-II into the circulatory system changes. With the effect of these
vasopressors, changes occur in SBP and DBP compared to their baseline
values<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>The changes in blood pressure after acute coronary syndromes (ACS) were demonstrated
to be associated with increased morbidity and mortality<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. For this reason, blood
pressure levels in risk scoring systems, which are used after ACS, rank as important
prognostic indicators<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Pulse pressure (PP) is the difference between SBP
and DBP. PP provides important information about the status of the arterial
circulation such as cardiac contraction and stiffness. It is suggested that the
power of PP for predicting cardiovascular events is higher than that of SBP and
DBP<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.
The PP of AMI patients, which is measured with the aid of a cuff from the arm at the
time of the first admission to the emergency service, is one of the determinants of
in-hospital and post-discharge long-term prognoses<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>]</sup>. However, the central
blood pressure measured from the aorta has a stronger association with early and
long-term outcomes of cardiovascular pathologies than the blood pressure measured
from the arm<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>In our study, we measured intra-aortic blood pressures of patients in whom primary
percutaneous coronary intervention (PPCI) was planned due to anterior ST-elevation
myocardial infarction (A-STEMI) with the aid of a catheter before PPCI. In line with
the guidelines, we included patients who had normal blood pressure range. We aimed
to evaluate the association of PP with mortality and major adverse cardiac events
(MACE) in one-year period after A-STEMI.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The patients of this study were gathered at a tertiary centre between August 2016 and
February 2017. The approval from the ethics committee was obtained prior to the
study, and all researchers completed the study in accordance with the Helsinki
Declaration.</p><p>Patients in whom less than 12 hours has passed after the onset of ST-elevation
myocardial infarction (STEMI) and who were taken to the angiography laboratory for
PPCI were evaluated. Those who had single vessel disease, age between 18 and 80
years, and left ventricular ejection fraction (LVEF) more than 25% were included in
our study. Since hypotensive periods were more frequent in inferior STEMIs, creating
a homogeneous group was aimed. Therefore, only patients with A-STEMI were included
in the study. Electrocardiographic examinations were performed during the period
when the patients were first admitted to the emergency department. Presence of ST
elevation &#x02265; 0.2 m in at least two of the precordial leads, newly developed
left bundle branch block, presence of chest pain with the typical onset and spread,
and cardiac troponin-I (c-TnI) and creatinine kinase-myocardial band (CK-MB) values
greater than the 99<sup>th</sup> percentile were considered as A-STEMI. Since our
centre has a team on call for 24/7, the patients were quickly taken to the
angiography laboratory after being diagnosed with A-STEMI.</p><p>Antiaggregant therapy of these patients (clopidogrel, 600 mg as a loading dose, 75
mg/day as maintenance dose; acetylsalicylic acid, 300 mg as a loading dose, 100
mg/day as maintenance dose) was initiated in the emergency service. Also,
concurrently, unfractionated heparin was administered via intravenous (IV) route at
the dose of 100 IU/kg. An additional dose of IV unfractionated heparin was
administered as needed so that the activated coagulation time would be &#x0003e;250.
Beta-blockers, statins, and renin-angiotensin-aldosterone system (RAAS) blockers
were initiated after PPCI according to the hemodynamic state in the intensive care
unit.</p><p>The exclusion criteria included passing more the 12 hours after the onset of A-STEMI,
previous AMI history, presence of known heart failure, presence of moderate to high
heart valve insufficiency and/or stenosis, glomerular filtration rate (GFR) less
than 30 ml/min/1.73 m<sup>2</sup>, chronic pulmonary disease, chronic liver disease,
and presence of previous cerebrovascular disease. In addition to these, patients
with previously diagnosed hypertension and who were on antihypertensive medication
were not included in the study. To minimise the effects of SBP and DBP levels on the
study's outcome, the condition of having these values within normal limits (100-140
mmHg for SBP and 60-90 mmHg for DBP) according to current hypertension guidelines
was applied. In our study, patients with hemodynamically unstable requirement of
inotropic agents and intra-aortic balloon pump (IABP) were excluded.</p><p>Blood pressure measurements were performed using a 6F pigtail catheter which was
placed in the ascending aorta just before coronary angiography. Before each
measurement, the pressure monitor was calibrated to zero. The system was rinsed with
heparinised liquid, and it was paid attention not to leave any air inside. The
transducer of the system to measure blood pressure was set at the same level with
the patient's heart. PP was calculated by subtracting DBP from SBP. The patients
were divided into three groups according to their PP: Group 1 included patients with
PP &#x0003c;35 mmHg, Group 2 included patients with 35&#x02264;PP&#x02264;50 mmHg, and
Group 3 included patients with PP&#x0003e; 50 mmHg.</p><p>The study's endpoints were accepted as all-cause mortality and MACE (death,
cardiogenic shock after PPCI, recurrent myocardial ischemia, re-myocardial
infarction [Re-MI], and stroke). Cardiogenic shock was defined as persistent
hypotension which does not respond to IABP placement, inotropic support, and fluid
support after PPCI and circulatory impairment. Re-MI was defined as recurring chest
pain, new electrocardiogram (ECG) changes, and increase of cardiac enzymes compared
to previous values. Stroke was defined as the presence of focal neurological deficit
which persists more than 24 hours and its confirmation with methods such as computed
tomography (CT) and magnetic resonance imaging (MRI). The SYNTAX score (STXs) was
calculated to determine the prevalence of coronary artery disease
(www.syntaxscore.com).</p><p>Echocardiographic examinations are performed routinely on AMI patients in the
emergency room of our centre; the patients are evaluated quickly, and images are
recorded. These examinations can be completed without a significant delay owing to
the presence of the angiography team and a cardiologist on call for 24/7 in the
emergency. Cardiac function, valve function, and complications at admission were
evaluated with echocardiography. The LVEF of all patients was calculated by the
modified Simpson method. Patients were followed-up for one year after A-STEMI; they
were called to outpatient clinics at 1, 3, 6, and 12 months.</p><sec><title>Statistical Analysis</title><p>In our study, the SPSS 17.0 (Chicago, Illinois, USA) program was used for
statistical analysis. Data distribution was checked by the Kolmogorov-Smirnov
test. Continuous variables were expressed as mean standard deviation (SD) or
median (interquartile range), according to their distribution status. Continuous
variables with normal distribution were compared with the analysis of variance
(ANOVA), those with non-normal distribution were compared with the Wilcoxon rank
test. Categorical variables were assessed with the chi-square test. Cumulative
survival and MACE curves were plotted, and log-rank analysis was performed using
the Kaplan-Meier method. Correlation analyses were performed to determine the
relationship between PP and LVEF, c-TnI, CK-MB, and symptom-to-door (StD) time.
Univariate analyses were performed with the variables, such as age, gender,
diabetes mellitus, heart rate, smoking, hyperlipidemia, SBP, DBP, PP, STXs,
LVEF, cTn-I, StD, door-to-balloon time (DtB), GFR, thrombolysis in myocardial
infarction (TIMI) flow grade, use of glycoprotein (GP) inhibitor, beta-blockers,
and RAAS inhibitors in order to determine the predictors of MACE. Backward
stepwise multivariate regression analysis was performed with variables of the
female gender, SBP, PP, LVEF, GFR, beta-blockers, RAAS inhibitors, and StD; the
<italic>P</italic> values of which was found to be
<italic>P</italic>&#x0003c;0.10 were evaluated by univariate analyses. Receiver
operating characteristic (ROC) analyses were performed to determine the PP
values associated with mortality and MACE. The area under the curve (AUC),
cut-off value, sensitivity, specificity, and confidence interval (CI) were
determined by ROC analyses. The <italic>P</italic> values &#x0003c;0.05 were accepted
as statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Of 297 patients who underwent PPCI with the diagnosis of A-STEMI in our clinic, 261
completed a one-year follow-up. Thirty-six patients who could not come to their
control meetings for the study or who could not be contacted afterwards were not
included in the statistical analysis. Of the studied patients, 206 were male and 55
were female. The male patient ratio was lower in Group 1. Mean age was calculated as
63.4&#x000b1;14.1 years. Means of smoking patients and SBP were higher in Groups 2
and 3. General characteristics, laboratory data, and medical treatments of the study
groups are shown in <xref rid="t1" ref-type="table">Table 1</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients&#x02019; demographic, laboratory, and angiographic characteristics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="28%" span="1"/><col width="18%" span="1"/><col width="18%" span="1"/><col width="18%" span="1"/><col width="18%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Group 1<break/>(n=74)</th><th align="center" rowspan="1" colspan="1">Group 2<break/>(n=107)</th><th align="center" rowspan="1" colspan="1">Group 3<break/>(n=80)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">62.7 (&#x000b1; 10.8)</td><td align="center" rowspan="1" colspan="1">62.8 (&#x000b1;13.4)</td><td align="center" rowspan="1" colspan="1">65.2 (&#x000b1;14.1)</td><td align="center" rowspan="1" colspan="1">0.450</td></tr><tr><td align="left" rowspan="1" colspan="1">Male [n (%)]</td><td align="center" rowspan="1" colspan="1">50 (67.6%)</td><td align="center" rowspan="1" colspan="1">87 (81.3%)</td><td align="center" rowspan="1" colspan="1">69 (86.3%)</td><td align="center" rowspan="1" colspan="1">0.013<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Female [n (%)]</td><td align="center" rowspan="1" colspan="1">24 (32.4%)</td><td align="center" rowspan="1" colspan="1">20 (18.7%)</td><td align="center" rowspan="1" colspan="1">11 (13.8%)</td><td align="center" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">27.3 (&#x000b1;7.1)</td><td align="center" rowspan="1" colspan="1">27.7 (&#x000b1;6.9)</td><td align="center" rowspan="1" colspan="1">27.8 (&#x000b1; 8.1)</td><td align="center" rowspan="1" colspan="1">0.645</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus [n (%)]</td><td align="center" rowspan="1" colspan="1">11 (14.9%)</td><td align="center" rowspan="1" colspan="1">22 (20.6%)</td><td align="center" rowspan="1" colspan="1">13 (16.3%)</td><td align="center" rowspan="1" colspan="1">0.569</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking [n (%)]</td><td align="center" rowspan="1" colspan="1">23 (31.1%)</td><td align="center" rowspan="1" colspan="1">57 (53.3%)</td><td align="center" rowspan="1" colspan="1">42 (52.5%)</td><td align="center" rowspan="1" colspan="1">0.006<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (bpm)</td><td align="center" rowspan="1" colspan="1">82.3 (&#x000b1;13.5)</td><td align="center" rowspan="1" colspan="1">86.6 (&#x000b1;16.2)</td><td align="center" rowspan="1" colspan="1">86.8 (&#x000b1;15.1)</td><td align="center" rowspan="1" colspan="1">0.241</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">112.3 (&#x000b1;14.4)</td><td align="center" rowspan="1" colspan="1">131.2 (&#x000b1; 8.3)</td><td align="center" rowspan="1" colspan="1">135.2 (&#x000b1; 4.6)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">76.1 (&#x000b1;12.5)</td><td align="center" rowspan="1" colspan="1">78.7 (&#x000b1;13.7)</td><td align="center" rowspan="1" colspan="1">74.2 (&#x000b1;9.7)</td><td align="center" rowspan="1" colspan="1">0.461</td></tr><tr><td align="left" rowspan="1" colspan="1">Haemoglobin (g/dl)</td><td align="center" rowspan="1" colspan="1">13.6 (&#x000b1;1.8)</td><td align="center" rowspan="1" colspan="1">14.1 (&#x000b1;1.8)</td><td align="center" rowspan="1" colspan="1">13.9 (&#x000b1;1.6)</td><td align="center" rowspan="1" colspan="1">0.231</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet (x10<sup>3</sup>)</td><td align="center" rowspan="1" colspan="1">238.2 (&#x000b1;54.5)</td><td align="center" rowspan="1" colspan="1">237.2 (&#x000b1;61.2)</td><td align="center" rowspan="1" colspan="1">239.7 (&#x000b1;49.2)</td><td align="center" rowspan="1" colspan="1">0.962</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose (mg/dl)</td><td align="center" rowspan="1" colspan="1">149.5 (&#x000b1;17.5)</td><td align="center" rowspan="1" colspan="1">154.6 (&#x000b1;21.2)</td><td align="center" rowspan="1" colspan="1">142.9 (&#x000b1;20.2)</td><td align="center" rowspan="1" colspan="1">0.513</td></tr><tr><td align="left" rowspan="1" colspan="1">CK-MB</td><td align="center" rowspan="1" colspan="1">155.9 (73.5-285.2)</td><td align="center" rowspan="1" colspan="1">132.2 (61.9-215.5)</td><td align="center" rowspan="1" colspan="1">147.3 (71.1-256.3)</td><td align="center" rowspan="1" colspan="1">0.372</td></tr><tr><td align="left" rowspan="1" colspan="1">Troponin-I (ng/dl)</td><td align="center" rowspan="1" colspan="1">75.4 (33.3-95.2)</td><td align="center" rowspan="1" colspan="1">76.3 (38.5-102.3)</td><td align="center" rowspan="1" colspan="1">77.3 (41.1-101.2)</td><td align="center" rowspan="1" colspan="1">0.989</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol (mg/dl)</td><td align="center" rowspan="1" colspan="1">122.6 (82.5-162.1)</td><td align="center" rowspan="1" colspan="1">128.8 (77.9-158.2)</td><td align="center" rowspan="1" colspan="1">123.2 (71.1-160.3)</td><td align="center" rowspan="1" colspan="1">0.592</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">0.97 (&#x000b1;0.18)</td><td align="center" rowspan="1" colspan="1">0.92 (&#x000b1;0.21)</td><td align="center" rowspan="1" colspan="1">0.94 (&#x000b1;0.19)</td><td align="center" rowspan="1" colspan="1">0.658</td></tr><tr><td align="left" rowspan="1" colspan="1">GFR (ml/dk/1.73 m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">83.1 (&#x000b1;17.4)</td><td align="center" rowspan="1" colspan="1">84.5 (&#x000b1;16.1)</td><td align="center" rowspan="1" colspan="1">91.6 (&#x000b1;20.1)</td><td align="center" rowspan="1" colspan="1">0.364</td></tr><tr><td align="left" rowspan="1" colspan="1">Symptom-to-balloon time (minutes)</td><td align="center" rowspan="1" colspan="1">307.3 (189.5-405.2)</td><td align="center" rowspan="1" colspan="1">288.8 (141.2-355.1)</td><td align="center" rowspan="1" colspan="1">295.1 (144.5-362.2)</td><td align="center" rowspan="1" colspan="1">0.893</td></tr><tr><td align="left" rowspan="1" colspan="1">Door-to-balloon time (minutes)</td><td align="center" rowspan="1" colspan="1">21.2 (14.8-26.5)</td><td align="center" rowspan="1" colspan="1">21.5 (12.2-30.1)</td><td align="center" rowspan="1" colspan="1">21.3 (11.2-28.9)</td><td align="center" rowspan="1" colspan="1">0.922</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction [n (%)]</td><td align="center" rowspan="1" colspan="1">35.9 (&#x000b1; 8.7)</td><td align="center" rowspan="1" colspan="1">38.7 (&#x000b1;7.4)</td><td align="center" rowspan="1" colspan="1">39.8 (&#x000b1;6.6)</td><td align="center" rowspan="1" colspan="1">0.174</td></tr><tr><td align="left" rowspan="1" colspan="1">Stent diameter (mm)</td><td align="center" rowspan="1" colspan="1">3.10 (2.46-3.70)</td><td align="center" rowspan="1" colspan="1">3.16 (2.55-3.42)</td><td align="center" rowspan="1" colspan="1">3.09 (2.48-3.41)</td><td align="center" rowspan="1" colspan="1">0.670</td></tr><tr><td align="left" rowspan="1" colspan="1">Stent length (mm)</td><td align="center" rowspan="1" colspan="1">25.09 (15.8-32.2)</td><td align="center" rowspan="1" colspan="1">25.61 (14.1-30.9)</td><td align="center" rowspan="1" colspan="1">25.25 (17.8-31.3)</td><td align="center" rowspan="1" colspan="1">0.966</td></tr><tr><td align="left" rowspan="1" colspan="1">Clopidogrel [n (%)]</td><td align="center" rowspan="1" colspan="1">71 (95.8%)</td><td align="center" rowspan="1" colspan="1">106 (99.1%)</td><td align="center" rowspan="1" colspan="1">79 (98.8%)</td><td align="center" rowspan="1" colspan="1">0.137</td></tr><tr><td align="left" rowspan="1" colspan="1">Acetylsalicylic acid [n (%)]</td><td align="center" rowspan="1" colspan="1">72 (97.3%)</td><td align="center" rowspan="1" colspan="1">107 (100.0%)</td><td align="center" rowspan="1" colspan="1">76 (95.0%)</td><td align="center" rowspan="1" colspan="1">0.075</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta-blocker [n (%)]</td><td align="center" rowspan="1" colspan="1">66 (89.2%)</td><td align="center" rowspan="1" colspan="1">99 (92.5%)</td><td align="center" rowspan="1" colspan="1">75 (93.8%)</td><td align="center" rowspan="1" colspan="1">0.560</td></tr><tr><td align="left" rowspan="1" colspan="1">RAAS blocker [n (%)]</td><td align="center" rowspan="1" colspan="1">65 (87.8%)</td><td align="center" rowspan="1" colspan="1">98 (91.6%)</td><td align="center" rowspan="1" colspan="1">72 (90.0%)</td><td align="center" rowspan="1" colspan="1">0.718</td></tr><tr><td align="left" rowspan="1" colspan="1">Statins [n (%)]</td><td align="center" rowspan="1" colspan="1">67 (90.5%)</td><td align="center" rowspan="1" colspan="1">101 (94.4%)</td><td align="center" rowspan="1" colspan="1">75 (93.8%)</td><td align="center" rowspan="1" colspan="1">0.581</td></tr><tr><td align="left" rowspan="1" colspan="1">Gp IIb-IIIa inhibitors [n (%)]</td><td align="center" rowspan="1" colspan="1">11 (16.2%)</td><td align="center" rowspan="1" colspan="1">16 (15.8%)</td><td align="center" rowspan="1" colspan="1">5 (7.0%)</td><td align="center" rowspan="1" colspan="1">0.178</td></tr><tr><td align="left" rowspan="1" colspan="1">SYNTAX score</td><td align="center" rowspan="1" colspan="1">24.2 (&#x000b1;8.9)</td><td align="center" rowspan="1" colspan="1">25.7 (&#x000b1;7.7)</td><td align="center" rowspan="1" colspan="1">26.2 (&#x000b1;11.3)</td><td align="center" rowspan="1" colspan="1">0.311</td></tr><tr><td align="left" rowspan="1" colspan="1">Intensive care unit (days)</td><td align="center" rowspan="1" colspan="1">3.20 (&#x000b1;0.9)</td><td align="center" rowspan="1" colspan="1">2.69 (&#x000b1;1.6)</td><td align="center" rowspan="1" colspan="1">3.16 (&#x000b1;1.1)</td><td align="center" rowspan="1" colspan="1">0.314</td></tr><tr><td align="left" rowspan="1" colspan="1">Total hospital stay (days)</td><td align="center" rowspan="1" colspan="1">6.00 (&#x000b1;1.9)</td><td align="center" rowspan="1" colspan="1">5.36 (&#x000b1;1.7)</td><td align="center" rowspan="1" colspan="1">6.15 (&#x000b1;1.9)</td><td align="center" rowspan="1" colspan="1">0.245</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>Data are expressed in numbers (%), mean&#x000b1;1SD, or median and
interquartile range.</p></fn><fn id="TFN02"><p>Percentages are rounded.</p></fn><fn id="TFN03"><label>*</label><p>Statistically significant.</p></fn><fn id="TFN04"><p>BMI=body mass index; CK-MB=creatinine kinase-myocardial band;
DBP=diastolic blood pressure; GFR=glomerular filtration rate;
Gp=glycoprotein; LDL=low-density lipropotein;
RAAS=renin-angiotensin-aldosterone system; SBP=systolic blood pressure;
SD=standard deviation</p></fn></table-wrap-foot></table-wrap><p>Mortality, MACE, cardiogenic shock, and newly-onset atrial fibrillation were more
frequent in Group 1 compared to other groups. Re-MI, major stroke, mechanical
complication, ventricular tachycardia, major bleeding, and TIMI flow grade &#x0003c;III
were similar. The distribution of adverse events, which were seen during the
one-year of follow-up, is shown in <xref rid="t2" ref-type="table">Table 2</xref>
and <xref ref-type="fig" rid="f1">Figure 1</xref>, according to the groups.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Morbidity, mortality, and MACE rates of in-hospital and post-PPCI one-year
period.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="28%" span="1"/><col width="18%" span="1"/><col width="18%" span="1"/><col width="18%" span="1"/><col width="18%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Low PP<break/>(n=74)</th><th align="center" rowspan="1" colspan="1">Moderate PP<break/>(n=107)</th><th align="center" rowspan="1" colspan="1">High PP<break/>(n=80)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MACE [n (%)]</td><td align="center" rowspan="1" colspan="1">27 (36.5%)</td><td align="center" rowspan="1" colspan="1">14 (13.1%)</td><td align="center" rowspan="1" colspan="1">11 (13.8%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TFN07">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mortality in one year [n (%)]</td><td align="center" rowspan="1" colspan="1">10 (13.5%)</td><td align="center" rowspan="1" colspan="1">2 (1.9%)</td><td align="center" rowspan="1" colspan="1">2 (2.5%)</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN07">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Killip class-I [n (%)]</td><td align="center" rowspan="1" colspan="1">41 (55.4%)</td><td align="center" rowspan="1" colspan="1">88 (82.2%)</td><td align="center" rowspan="1" colspan="1">67 (83.8%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TFN07">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Killip class-II [n (%)]</td><td align="center" rowspan="1" colspan="1">14 (18.9%)</td><td align="center" rowspan="1" colspan="1">13 (12.1%)</td><td align="center" rowspan="1" colspan="1">8 (10.0%)</td><td align="center" rowspan="1" colspan="1">0.236</td></tr><tr><td align="left" rowspan="1" colspan="1">Killip class-III [n (%)]</td><td align="center" rowspan="1" colspan="1">6 (8.1%)</td><td align="center" rowspan="1" colspan="1">3 (2.8%)</td><td align="center" rowspan="1" colspan="1">4 (5.0%)</td><td align="center" rowspan="1" colspan="1">0.314</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiogenic shock after PPCI [n (%)]</td><td align="center" rowspan="1" colspan="1">13 (17.6%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;3 (2.8%)</td><td align="center" rowspan="1" colspan="1">1 (1.3%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TFN07">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Re-MI [n (%)]</td><td align="center" rowspan="1" colspan="1">4 (5.4%)</td><td align="center" rowspan="1" colspan="1">6 (5.6%)</td><td align="center" rowspan="1" colspan="1">6 (7.5%)</td><td align="center" rowspan="1" colspan="1">0.798</td></tr><tr><td align="left" rowspan="1" colspan="1">Major stroke [n (%)]</td><td align="center" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" rowspan="1" colspan="1">2 (1.9%)</td><td align="center" rowspan="1" colspan="1">2 (2.5%)</td><td align="center" rowspan="1" colspan="1">0.924</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation after STEMI [n (%)]</td><td align="center" rowspan="1" colspan="1">6 (8.1%)</td><td align="center" rowspan="1" colspan="1">1 (0.9%)</td><td align="center" rowspan="1" colspan="1">1 (1.3%)</td><td align="center" rowspan="1" colspan="1">0.012<xref ref-type="table-fn" rid="TFN07">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mechanical complication [n (%)]</td><td align="center" rowspan="1" colspan="1">3 (4.4%)</td><td align="center" rowspan="1" colspan="1">1 (0.9%)</td><td align="center" rowspan="1" colspan="1">2 (2.5%)</td><td align="center" rowspan="1" colspan="1">0.381</td></tr><tr><td align="left" rowspan="1" colspan="1">Ventricular tachycardia [n (%)]</td><td align="center" rowspan="1" colspan="1">6 (8.1%)</td><td align="center" rowspan="1" colspan="1">2 (1.9%)</td><td align="center" rowspan="1" colspan="1">2 (2.5%)</td><td align="center" rowspan="1" colspan="1">0.075</td></tr><tr><td align="left" rowspan="1" colspan="1">Major bleeding [n (%)]</td><td align="center" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" rowspan="1" colspan="1">1 (0.9%)</td><td align="center" rowspan="1" colspan="1">4 (5.0%)</td><td align="center" rowspan="1" colspan="1">0.108</td></tr><tr><td align="left" rowspan="1" colspan="1">TIMI-0 flow rate after PPCI [n (%)]</td><td align="center" rowspan="1" colspan="1">4 (5.4%)</td><td align="center" rowspan="1" colspan="1">3 (2.8%)</td><td align="center" rowspan="1" colspan="1">3 (3.8%)</td><td align="center" rowspan="1" colspan="1">0.675</td></tr><tr><td align="left" rowspan="1" colspan="1">TIMI-I/II flow rate after PPCI [n (%)]</td><td align="center" rowspan="1" colspan="1">9 (12.2%)</td><td align="center" rowspan="1" colspan="1">5 (4.7%)</td><td align="center" rowspan="1" colspan="1">5 (6.3%)</td><td align="center" rowspan="1" colspan="1">0.148</td></tr></tbody></table><table-wrap-foot><fn id="TFN05"><p>Data are expressed in numbers (%), mean&#x000b1;1SD, or median and
interquartile range.</p></fn><fn id="TFN06"><p>Percentages are rounded.</p></fn><fn id="TFN07"><label>*</label><p>Statistically significant.</p></fn><fn id="TFN08"><p>MACE=major adverse cardiac events; MI=myocardial infarction; PP=pulse
pressure; PPCI=primary percutaneous coronary intervention; SD=standard
deviation; STEMI=ST-elevation myocardial infarction; TIMI=thrombolysis
in myocardial infarction</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Distribution of patients with major adverse cardiac events (MACE) during
one-year follow-up according to the study groups.</p></caption><graphic xlink:href="rbccv-33-06-0579-g01"/></fig>
</p><p>In the ROC analysis, the predictive PP value was calculated as 42.5 mmHg for MACE
development and 41.5 mmHg for mortality (<xref ref-type="fig" rid="f2">Figure
2</xref>, <xref ref-type="fig" rid="f3">Figure 3</xref>). The patients' annual
life expectancy assessed by the Kaplan-Meier method was lower in Group 1 (<xref ref-type="fig" rid="f4">Figure 4</xref>). There was a low positive correlation
between LVEF, PP, and StD.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>The pulse pressure value which can predict the occurrence of mortality
during one-year follow-up was determined as 41.5 mmHg in receiver
operating characteristics analysis.</p><p>AUC=area under the curve</p></caption><graphic xlink:href="rbccv-33-06-0579-g02"/></fig>
</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>The pulse pressure value which can predict the occurrence of major
adverse cardiac events (MACE) rates during one-year follow-up was
determined as 42.5 mmHg in receiver operating characteristics
analysis.</p><p>AUC=area under the curve</p></caption><graphic xlink:href="rbccv-33-06-0579-g03"/></fig>
</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>One-year survival rate in Group 1 was detected lower than in other groups
in Kaplan-Meier survival analysis. Cum=cumulative; PP=pulse pressure;
PPR=pulse pressure ratio</p></caption><graphic xlink:href="rbccv-33-06-0579-g04"/></fig>
</p><p>After univariate and multivariate analyses carried out with the variables that could
affect mortality, LVEF, inability to initiate beta-blockers in the acute period, PP,
SBP, GFR, and STD were determined to be mortality predictors (<xref rid="t3" ref-type="table">Tables 3</xref> and <xref rid="t4" ref-type="table">4</xref>). After
additional adjustment for SBP, PP remained an independent predictor of mortality
(hazard ratio [HR] 2.1 [1.2 to 4.3], <italic>P</italic>=0.034 <italic>vs</italic>.
HR 1.6 [1.1 to 3.1], <italic>P</italic>=0.041).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Variables which effect MACE according to univariate analysis results.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="35%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Predictor variables</th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">0.7 (0.4-1.1)</td><td align="center" rowspan="1" colspan="1">0.599</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (female)</td><td align="center" rowspan="1" colspan="1">1.4 (0.7-1.9)</td><td align="center" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">0.8 (0.5-1.3)</td><td align="center" rowspan="1" colspan="1">0.344</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP</td><td align="center" rowspan="1" colspan="1">1.9 (1.0-3.1)</td><td align="center" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP</td><td align="center" rowspan="1" colspan="1">0.9 (0.5-1.5)</td><td align="center" rowspan="1" colspan="1">0.167</td></tr><tr><td align="left" rowspan="1" colspan="1">PP</td><td align="center" rowspan="1" colspan="1">2.5 (1.4-5.1)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">SYNTAX score</td><td align="center" rowspan="1" colspan="1">0.7 (0.5-1.0)</td><td align="center" rowspan="1" colspan="1">0.484</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction</td><td align="center" rowspan="1" colspan="1">5.7 (2.8-8.1)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No-beta-blocker</td><td align="center" rowspan="1" colspan="1">3.7 (1.6-7.0)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No-RAAS blockers</td><td align="center" rowspan="1" colspan="1">1.7 (1.0-3.0)</td><td align="center" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" rowspan="1" colspan="1">Symptom-to-balloon time</td><td align="center" rowspan="1" colspan="1">1.9 (0.9-3.6)</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Door-to-balloon time</td><td align="center" rowspan="1" colspan="1">1.0 (0.7-1.5)</td><td align="center" rowspan="1" colspan="1">0.198</td></tr><tr><td align="left" rowspan="1" colspan="1">Gp IIb-IIIa receptor blockers</td><td align="center" rowspan="1" colspan="1">0.8 (0.4-1.8)</td><td align="center" rowspan="1" colspan="1">0.323</td></tr><tr><td align="left" rowspan="1" colspan="1">Haemoglobin</td><td align="center" rowspan="1" colspan="1">1.1 (0.7-1.4)</td><td align="center" rowspan="1" colspan="1">0.144</td></tr><tr><td align="left" rowspan="1" colspan="1">GFR</td><td align="center" rowspan="1" colspan="1">1.9 (0.9-2.7)</td><td align="center" rowspan="1" colspan="1">0.012</td></tr></tbody></table><table-wrap-foot><fn id="TFN09"><p>CI=confidence interval; DBP=diastolic blood pressure;</p></fn><fn id="TFN10"><p>GFR=glomerular filtration rate; Gp=glycoprotein;</p></fn><fn id="TFN11"><p>MACE=major adverse cardiac events; OR=odds ratio;</p></fn><fn id="TFN12"><p>PP=pulse pressure; RAAS=renin-angiotensin-aldosterone system;
SBP=systolic blood pressure</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Variables which effect MACE according to multivariate analysis results.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="35%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Predictor variables</th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (female)</td><td align="center" rowspan="1" colspan="1">0.8 (0.7-1.3)</td><td align="center" rowspan="1" colspan="1">0.124</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP</td><td align="center" rowspan="1" colspan="1">1.9 (0.9-2.8)</td><td align="center" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">PP</td><td align="center" rowspan="1" colspan="1">2.3 (1.6-4.7)</td><td align="center" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" rowspan="1" colspan="1">SYNTAX score</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction</td><td align="center" rowspan="1" colspan="1">4.1 (1.9-6.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No-beta-blocker</td><td align="center" rowspan="1" colspan="1">2.9 (1.6-5.1)</td><td align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">No-RAAS blockers</td><td align="center" rowspan="1" colspan="1">1.1 (0.4-2.0)</td><td align="center" rowspan="1" colspan="1">0.098</td></tr><tr><td align="left" rowspan="1" colspan="1">Symptom-to-balloon time</td><td align="center" rowspan="1" colspan="1">2.4 (1.4-3.9)</td><td align="center" rowspan="1" colspan="1">0.037</td></tr><tr><td align="left" rowspan="1" colspan="1">Door-to-balloon time</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Gp IIb-IIIa receptor blockers</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Haemoglobin</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">GFR</td><td align="center" rowspan="1" colspan="1">2.1 (0.8-3.2)</td><td align="center" rowspan="1" colspan="1">0.048</td></tr></tbody></table><table-wrap-foot><fn id="TFN13"><p>CI=confidence interval; DBP=diastolic blood pressure;</p></fn><fn id="TFN14"><p>GFR=glomerular filtration rate; Gp=glycoprotein;</p></fn><fn id="TFN15"><p>MACE=major adverse cardiac events; OR=odds ratio;</p></fn><fn id="TFN16"><p>PP=pulse pressure; RAAS=renin-angiotensin-aldosterone system;
SBP=systolic blood pressure</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In our study, it was determined that the PP measured in A-STEMI patients
intra-aortically before PPCI was significantly associated with MACE.</p><p>Many studies have discussed the relationship between blood pressure and prognosis for
many years. The first blood pressure studies suggested that DBP is the main
determinant of prognosis<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. The studies in the following years suggested the
idea that SBP is more important and it is not necessary to evaluate DBP for
prognosis<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Afterwards, the studies that evaluated the
relationship between ACS and blood pressure were concluded. SBP &#x0003c; 90 mmHg after
AMI was generally considered to be a poor prognostic indicator<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Various risk scoring
systems were developed as a result of this data. Blood pressure irregularity was
rated as a significant negative indicator<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. It is known that high blood pressure in
patients with ACS is associated with cardiovascular complications as much as low
blood pressure. AMI blood pressure studies usually assessed SBP levels. However, in
a small number of studies, it was determined that the DBP not within the normal
limits after ACS was associated with increase in mortality and
morbidity<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. All these evaluations showed that blood pressure
out of the normal limits in AMI patients is a bad indicator. The changes in PP
calculated according to SBP and DBP are indicative of stiffness of vascular bed. The
dramatic decrease in CO and peripheral resistance in the patients with ACS, heart
failure, aortic stenosis, and septic shock were shown to cause a decrease in PP.
Significant changes in PP were determined to increase morbidity and
mortality<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>.</p><p>Li et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>
indicated that PP lower than 50 mm and higher than 70 mmHg increased the mortality
rates significantly in patients with ACS who were over 80 years old. Patients with
PP between these two values had the best prognosis. In this study, no upper or lower
limit was determined for blood pressure values. Patients with blood pressure values
between 170/100 mmHg and 130/60 mmHg were considered similarly since their PP was 70
mmHg<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.
In our study, A-STEMI patients with normal SBP and DBP were followed according to
the recommendations of current guidelines. Thereby, the association of PP with the
emerging cardiovascular events in patients with normal SBP and DBP intervals was
attempted to be determined. Patients in Group 1 who had PP lower than 35 mmHg were
found to have the worst prognosis. The highest mortality and MACE rates were also in
this group. Li et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> e El-Menyar et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> also showed that PP
reduction in patients with ACS was associated with stroke and mortality. In both
studies, PP was calculated according to the blood pressure values measured from the
arm by experienced health personnel. Li et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> followed-up the patients with AMI while
El-Menyar et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> followed-up all patients with ACS. As it is known,
in all the ACS subgroups, CO does not fall to the same level, and the neuroendocrine
system is not activated at the same degree. Additionally, cardiac functions do not
change at similar levels in all STEMIs. Blood pressure levels tend to be lower due
to decreased stroke volume and increased vagal stimulation in inferior
STEMI<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Therefore, only A-STEMI patients were accepted in
order to create a homogenous group.</p><p>In the previous studies<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>, the central blood pressure obtained with the aid
of aortic catheter was shown to have a stronger association with cardiovascular
outcomes than that measured from the arm. Thus, central blood pressure measurements
obtained from the ascending aorta with the aid of catheter before PPCI in the
coronary angiography laboratory were taken into consideration in our study. As a
result of one-year follow-up, an increased number of deaths, cardiogenic shocks
after PPCI, and total MACE ratios were detected in Group 1 compared to other groups.
The prevalence of LVEF and coronary artery disease was similar among the groups. The
rate of female patients in Group 1 was higher than in other groups. As it is known,
the pain threshold is higher in women, and the microvascular circulation dynamics
and complication rates after AMI are increased compared to men<sup>[<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. These findings are
supported by the high number of female patients in Group 1 with higher rates of
mortality and MACE in our study.</p><p>When the Kaplan-Meier curves were evaluated, the survival rate in Group 1 was worse
than in other groups. There was no difference in survival expectancy between Group 2
and Group 3. The PP level limit, which could increase MACE rates, was determined as
42.5 mmHg in the ROC analysis. The PP value, which could predict one-year mortality,
was found to be 41.5 mmHg. The risk of developing cardiovascular events was
determined to be increased below these values. According to multivariate analysis,
the predictors of mortality were determined to be PP, SBP, lower LVEF, inability to
initiate beta-blockers in the acute phase, lower GFR, and STD time.</p><p>Statistical analyses revealed that SBP and PP were associated with the complications
that could develop. However, the predictive power of PP was found to be higher than
the one of SBP (<xref rid="t3" ref-type="table">Table 3</xref>). This may be due to
the fact that patients with SBP values within the normal range were included. Also,
PP is directly related to cardiac perfusion<sup>[<xref rid="r20" ref-type="bibr">20</xref>-<xref rid="r22" ref-type="bibr">22</xref>]</sup>. Myocardial perfusion pressure decreases with
the decrease of PP. Even if SBP is decreased, the PP can maintain coronary perfusion
by staying constant for a certain period. However, the reduction of PP reduces
coronary perfusion. Myocardium recovery may be delayed after A-STEMI and sometimes
may not be possible due to decreased perfusion. The reduction in PP is an important
condition which can increase cardiovascular complication rates due to these
reasons.</p><p>In our study, the inability to initiate beta-blockers in the acute phase of the
disease was one of the poor prognostic factors. The patients in whom beta-blockers
could not be initiated included those who generally had hemodynamic instability and
were unable to optimise medical treatments fully. Therefore, we think that there is
a significant relationship between beta-blockers and prognosis.</p><p>Li et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>
showed that there is a positive correlation between LVEF and PP. There was no
significant difference between the groups in terms of the mean LVEF in our study.
However, in the correlation analyses, it was determined that there was a low
positive correlation between the decline in PP and LVEF and the prolongation of StD
period. This condition suggests that cardiovascular complications following STEMI
are associated with other variables apart from LVEF. It may be useful to consider
the changes in PP other than LVEF.</p><sec><title>Limitations</title><p>Our study's main limitation was the low number of patients. The study was
conducted in one centre. Blood pressure values are dynamic parameters especially
in patients with STEMI, and sedation, agitation, and inotropic agents may affect
these values. In our study, patients with hemodynamically unstable requirement
of inotropic agents and IABP were excluded. We can't extend this result's
validity to hypotensive patients due to the fact that hemodynamically stable
patients were included in our study. The normalisation of PP with systolic
arterial pressure (PAS) or diastolic arterial pressure (PAD) might be beneficial
to predict the adequacy of coronary perfusion. PP has been registered with a
water-filled catheter and not with high-fidelity catheters. This may reduce the
quality of the measurement in patients with lower PP. Although poorly
significant differences emerged between Group 2 and Group 3, patients were
divided into three groups to see the effect of the extreme values on the
results. Some of the recommended pharmacological treatments after STEMI in the
current guidelines could not be initiated in the patients with hemodynamic
instability at the same or in similar doses to the other patients. The left
ventricular end-diastolic pressure (LVEDP) could not be calculated by entering
the left ventricle to avoid time loss since the patients had A-STEMI. If LVEDP
could have been calculated, more accurate results could have been obtained by
assessing perfusion pressure. These measurements can be performed in STEMI
patients whose general conditions are stable. In our study, there was a
significant difference between the groups in terms of means of SBP. Although SBP
values were not the same, unlike other studies, they were in the range
considered as normal by guidelines.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In our study, the central PP measured intra-aortically before PPCI in patients with
A-STEMI in the angiography laboratory was significantly associated with MACE.
Therefore, even if the blood pressure of patients with A-STEMI is within normal
limits, it is good to evaluate the changes in PP carefully while arranging follow-up
and treatment. Including PP in the algorithms while calculating the risk levels of
patients after AMI might be beneficial.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="7%" span="1"/><col width="93%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1"><bold>Authors&#x02019; roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IG</td><td align="left" rowspan="1" colspan="1">Analysis and interpretation of data; drafting the
paper; revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">LC</td><td align="left" rowspan="1" colspan="1">Analysis and interpretation of data; drafting the
paper; revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">BS</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">MBA</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">HK</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">ZC</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">BY</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">SU</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">HD</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
analysis and interpretation of data; drafting the paper; revising
the work; approval of the final version</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Near East University Hospital, Near East Boulevard,
Nicosia, Cyprus.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunstall-Pedoe</surname><given-names>H</given-names></name><name><surname>Kuulasmaa</surname><given-names>K</given-names></name><name><surname>M&#x000e4;h&#x000f6;nen</surname><given-names>M</given-names></name><name><surname>Tolonen</surname><given-names>H</given-names></name><name><surname>Ruokokoski</surname><given-names>E</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name></person-group><article-title>Contribution of trends in survival and coronary-event rates to
changes in coronary heart disease mortality: 10-year results from 37 WHO
MONICA project populations. Monitoring trends and determinants in
cardiovascular disease</article-title><source>Lancet</source><year>1999</year><volume>353</volume><issue>9164</issue><fpage>1547</fpage><lpage>1557</lpage><pub-id pub-id-type="pmid">10334252</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillis</surname><given-names>LD</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Myocardial ischemia (first of three parts)</article-title><source>N Engl J Med</source><year>1977</year><volume>296</volume><issue>17</issue><fpage>971</fpage><lpage>978</lpage><pub-id pub-id-type="pmid">191753</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>GF</given-names></name><name><surname>Moy&#x000e9;</surname><given-names>LA</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Rouleau</surname><given-names>JL</given-names></name><name><surname>Bernstein</surname><given-names>V</given-names></name><name><surname>Geltman</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Sphygmomanometrically determined pulse pressure is a powerful
independent predictor of recurrent events after myocardial infarction in
patients with impaired left ventricular function</article-title><person-group person-group-type="author"><collab>SAVE investigators</collab></person-group><comment>Survival and Ventricular Enlargement</comment><source>Circulation</source><year>1997</year><volume>96</volume><issue>12</issue><fpage>4254</fpage><lpage>4260</lpage><pub-id pub-id-type="pmid">9416890</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Pieper</surname><given-names>KS</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><name><surname>Wilcox</surname><given-names>RG</given-names></name><name><surname>Chang</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Predictors of outcome in patients with acute coronary syndromes
without persistent ST-segment elevation. Results from an international trial
of 9461 patients.</article-title><person-group person-group-type="author"><collab>The PURSUIT Investigators</collab></person-group><source>Circulation</source><year>2000</year><volume>101</volume><issue>22</issue><fpage>2557</fpage><lpage>2567</lpage><pub-id pub-id-type="pmid">10840005</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>DA</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Charlesworth</surname><given-names>A</given-names></name><name><surname>Cairns</surname><given-names>R</given-names></name><name><surname>Murphy</surname><given-names>SA</given-names></name><name><surname>Lemos</surname><given-names>JA</given-names></name><etal/></person-group><article-title>TIMI risk score for ST-elevation myocardial infarction: a
convenient, bedside, clinical score for risk assessment at presentation. An
intravenous nPA for treatment of infracting myocardium early II trial
substudy</article-title><source>Circulation</source><year>2000</year><volume>102</volume><issue>17</issue><fpage>2031</fpage><lpage>2037</lpage><pub-id pub-id-type="pmid">11044416</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Cullen</surname><given-names>P</given-names></name><name><surname>Evers</surname><given-names>T</given-names></name><name><surname>Petzinna</surname><given-names>D</given-names></name><name><surname>Schulte</surname><given-names>H</given-names></name></person-group><article-title>Importance of arterial pulse pressure as a predictor of coronary
heart disease risk in PROCAM</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><issue>20</issue><fpage>2120</fpage><lpage>2126</lpage><pub-id pub-id-type="pmid">16141262</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Barywani</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name></person-group><article-title>Prognostic power of lower pulse pressure on long-term all-cause
mortality in octogenarians with acute coronary syndrome: a
propensity-score-matched cohort study</article-title><source>J Hypertens</source><year>2015</year><volume>33</volume><issue>2</issue><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">25318655</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Menyar</surname><given-names>A</given-names></name><name><surname>Zubaid</surname><given-names>M</given-names></name><name><surname>Almahmeed</surname><given-names>W</given-names></name><name><surname>Alanbaei</surname><given-names>M</given-names></name><name><surname>Rashed</surname><given-names>W</given-names></name><name><surname>Al Qahtani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Initial hospital pulse pressure and cardiovascular outcomes in
acute coronary syndrome</article-title><source>Arch Cardiovasc Dis</source><year>2011</year><volume>104</volume><issue>8-9</issue><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">21944145</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>MJ</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Kizer</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>ET</given-names></name><name><surname>Galloway</surname><given-names>JM</given-names></name><name><surname>Ali</surname><given-names>T</given-names></name><etal/></person-group><article-title>Central pressure more strongly relates to vascular disease and
outcome than does brachial pressure: the Strong Heart Study</article-title><source>Hypertension</source><year>2007</year><volume>50</volume><issue>1</issue><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">17485598</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avolio</surname><given-names>A</given-names></name></person-group><article-title>Central aortic blood pressure and cardiovascular risk: a paradigm
shift?</article-title><source>Hypertension</source><year>2008</year><volume>51</volume><issue>6</issue><fpage>1470</fpage><lpage>1471</lpage><pub-id pub-id-type="pmid">18426994</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><article-title>Effects of treatment on morbidity in hypertension. Results in
patients with diastolic blood pressures averaging 115 through 129 mm
Hg</article-title><source>JAMA</source><year>1967</year><volume>202</volume><issue>11</issue><fpage>1028</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">4862069</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Wentworth</surname><given-names>D</given-names></name></person-group><article-title>Serum cholesterol, blood pressure, cigarette smoking, and death
from coronary heart disease. Overall findings and differences by age for
316,099 white men</article-title><person-group person-group-type="author"><collab>Multiple Risk Factor Intervention Trial Research Group</collab></person-group><source>Arch Intern Med</source><year>1992</year><volume>152</volume><issue>1</issue><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">1728930</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitsavos</surname><given-names>C</given-names></name><name><surname>Panagiotakos</surname><given-names>D</given-names></name><name><surname>Zombolos</surname><given-names>S</given-names></name><name><surname>Mantas</surname><given-names>Y</given-names></name><name><surname>Antonoulas</surname><given-names>A</given-names></name><name><surname>Stravopodis</surname><given-names>P</given-names></name><etal/><collab>Greek Study of Acute Coronary Syndromes Investigators Group</collab></person-group><article-title>Systolic blood pressure on admission predicts in-hospital
mortality among patients presenting with acute coronary syndromes: the Greek
study of acute coronary syndromes</article-title><source>J Clin Hypertens (Greenwich)</source><year>2008</year><volume>10</volume><issue>5</issue><fpage>362</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">18453795</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eagle</surname><given-names>KA</given-names></name><name><surname>Lim</surname><given-names>MJ</given-names></name><name><surname>Dabbous</surname><given-names>OH</given-names></name><name><surname>Pieper</surname><given-names>KS</given-names></name><name><surname>Goldberg</surname><given-names>RJ</given-names></name><name><surname>Van de Werf</surname><given-names>F</given-names></name><etal/><collab>GRACE Investigators</collab></person-group><article-title>A validated prediction model for all forms of acute coronary
syndrome: estimating the risk of 6-month postdischarge death in an
international registry</article-title><source>JAMA</source><year>2004</year><volume>291</volume><issue>22</issue><fpage>2727</fpage><lpage>2733</lpage><pub-id pub-id-type="pmid">15187054</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawase</surname><given-names>Y</given-names></name><name><surname>Kadota</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Tada</surname><given-names>T</given-names></name><name><surname>Hata</surname><given-names>R</given-names></name><name><surname>Miyawaki</surname><given-names>H</given-names></name><etal/></person-group><article-title>Low systolic blood pressure on admission predicts mortality in
patients with acute decompensated heart failure due to moderate to severe
aortic stenosis</article-title><source>Circ J</source><year>2014</year><volume>78</volume><issue>10</issue><fpage>2455</fpage><lpage>2459</lpage><pub-id pub-id-type="pmid">25168190</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zornoff</surname><given-names>LA</given-names></name><name><surname>Skali</surname><given-names>H</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>St John Sutton</surname><given-names>M</given-names></name><name><surname>Rouleau</surname><given-names>JL</given-names></name><name><surname>Lamas</surname><given-names>GA</given-names></name><etal/><collab>SAVE Investigators</collab></person-group><article-title>Right ventricular dysfunction and risk of heart failure and
mortality after myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>39</volume><issue>9</issue><fpage>1450</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">11985906</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Rourke</surname><given-names>RA</given-names></name><name><surname>Dell'Italia</surname><given-names>LJ</given-names></name></person-group><article-title>Diagnosis and management of right ventricular myocardial
infarction</article-title><source>Curr Probl Cardiol</source><year>2004</year><volume>29</volume><issue>1</issue><fpage>6</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">14872197</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JS</given-names></name><name><surname>Elliott</surname><given-names>L</given-names></name><name><surname>Gallup</surname><given-names>D</given-names></name><name><surname>Roe</surname><given-names>M</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Sex differences in mortality following acute coronary
syndromes</article-title><source>JAMA</source><year>2009</year><volume>302</volume><issue>8</issue><fpage>874</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">19706861</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bairey Merz</surname><given-names>CN</given-names></name><name><surname>Shaw</surname><given-names>LJ</given-names></name><name><surname>Reis</surname><given-names>SE</given-names></name><name><surname>Bittner</surname><given-names>V</given-names></name><name><surname>Kelsey</surname><given-names>SF</given-names></name><name><surname>Olson</surname><given-names>M</given-names></name><etal/><collab>WISE Investigators</collab></person-group><article-title>Insights from the NHLBI-Sponsored Women's Ischemia Syndrome
Evaluation (WISE) Study: Part II: gender differences in presentation,
diagnosis, and outcome with regard to gender-based pathophysiology of
atherosclerosis and macrovascular and microvascular coronary
disease</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>47</volume><issue>3 Suppl</issue><fpage>S21</fpage><lpage>S29</lpage><pub-id pub-id-type="pmid">16458167</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabkin</surname><given-names>SW</given-names></name><name><surname>Waheed</surname><given-names>A</given-names></name><name><surname>Poulter</surname><given-names>RS</given-names></name><name><surname>Wood</surname><given-names>D</given-names></name></person-group><article-title>Myocardial perfusion pressure in patients with hypertension and
coronary artery disease: implications for DBP targets in hypertension
management</article-title><source>J Hypertens</source><year>2013</year><volume>31</volume><issue>5</issue><fpage>975</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">23511338</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruickshank</surname><given-names>JM</given-names></name></person-group><article-title>Clinical importance of coronary perfusion pressure in the
hypertensive patient with left ventricular hypertrophy</article-title><source>Cardiology</source><year>1992</year><volume>81</volume><issue>4-5</issue><fpage>283</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">1301256</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feigl</surname><given-names>EO</given-names></name><name><surname>Neat</surname><given-names>GW</given-names></name><name><surname>Huang</surname><given-names>AH</given-names></name></person-group><article-title>Interrelations between coronary artery pressure, myocardial
metabolism and coronary blood flow</article-title><source>J Mol Cell Cardiol</source><year>1990</year><volume>22</volume><issue>4</issue><fpage>375</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">2388275</pub-id></element-citation></ref></ref-list></back></article>